Table 2.
Clinical and medication characteristics of the tuberculosis patients at Nekemte specilaized hospital, 2013–2019.
| HIV related characteristics | Frequency(n) | Percentage (%) | |
|---|---|---|---|
| Type of TB | PTB+ | 192 | 37.9 |
| PTB- | 193 | 38.1 | |
| EPTB | 121 | 23.9 | |
| TB registration status (TB enrollment) | New | 446 | 88.1 |
| Relapse | 42 | 8.3 | |
| Treatment failure | 10 | 2.0 | |
| Treatment after default | 8 | 1.6 | |
| INH Propylaxis | Yes | 33 | 6.5 |
| No | 324 | 93.5 | |
| HIV status | Reactive | 124 | 24.5 |
| Non-reactive | 347 | 68.6 | |
| Indeterminate | 35 | 6.9 | |
| CD4 count during TB diagnosis (Cells/mm3) [n = 124] | ≥200 | 21 | 17 |
| 50–199 | 37 | 30 | |
| <50 | 66 | 53 | |
| WHO HVI stage during TB diagnosis [n = 124] | Stage I | 6 | 4.9 |
| Stage II | 9 | 7 | |
| Stage III | 36 | 29 | |
| Stage IV | 73 | 58.9 | |
| Enrolled in HIV care [n = 124] | Yes | 115 | 92.7 |
| No | 9 | 7.3 | |
| CPT given [n = 124] | Yes | 110 | 88.7 |
| No | 14 | 11.3 | |
| Started ART [n = 124] | Yes | 105 | 84.7 |
| No | 19 | 15.3 | |
| ART regimen at TB diagnosis [n = 124] | TDF-3TC-NVP | 65 | 52.42 |
| TDF-3TC-EFV | 37 | 29.84 | |
| D4t-3TC-NVP | 9 | 7.26 | |
| AZT-3TC-EFV | 5 | 4.03 | |
| ABC-3TC-EFV | 5 | 4.03 | |
| AZT-3TC-NVP | 3 | 2.42 | |
| Second line regimens | 65 | 52.42 | |
| INH Propylaxis | Yes | 64 | 12.6 |
| No | 442 | 87.4 | |
| Functional status | Working | 341 | 67.4 |
| Ambulatory | 125 | 24.7 | |
| Bedriden | 40 | 7.9 | |
| Nutritional status | Malnourished | 191 | 37.7 |
| Not malnourished | 315 | 62.3 | |
| Presence of comorbidity (n = 232) | HIV | 124 | 53.4 |
| Other RTI (including Asthma) | 31 | 13.3 | |
| Cardiovascular disorders (HTN, IHD, HF) | 27 | 10.3 | |
| Diabetes Mellitus | 21 | 9.1 | |
| Pschiatric disorders (depression and anxiety | 16 | 6.9 | |
| Renal diseases | 9 | 3.9 | |
| Anemia | 4 | 1.7 | |
| Treatment associated adverse effects (toxicity) | yes | yes | 143 |
| No | No | 363 | |
ART: Antiretroviral treatment; CD4: Cluster differentiation-4, HIV: Human immune virus; WHO: World health organization. EPTB: Extra-pulmonary Tuberculosis; TB: Tuberculosis; PTB+: Pulmonary positive TB, PTB-: Pulmonary negative TB; INH: Isoniazid; CPT: Cotrimoxazole preventive therapy, ABC: Abacavir; TDF: Tenofovir fumarate; 3 TC: Lamivudine, D4T: Stavudine; AZT: Zidovudine; EFV: Efavirenz; NVP: Nevirapine; HTN: Hypertension; IHD: Ischemic heart diseases; HF: Heart failure; RTI: Respiratory tract infection.